Results 251 to 260 of about 302,518 (309)

Effects of Non-Alcoholic Fatty Liver Disease on Baseline Histology and 96-Week Entecavir Response in Treatment-Naïve Chronic Hepatitis B. [PDF]

Infect Drug Resist
Gu X, Yang W, Hu Y, Li Y, Zheng L, Jiang B.   +5 more
europepmc   +1 more source

Rapidly Progressive IgA Nephropathy in a Patient with Systemic Lupus Erythematosus and Chronic Hepatitis B: A Case Report. [PDF]

Reports (MDPI)
Kleinová P, Graňák K, Blichová T, Vnučák M, Dedinská I.   +4 more
europepmc   +1 more source

Diagnosis and treatment of chronic hepatitis B in women of child-bearing age and strategies for blocking mother-to-child transmission

, 2019
Han Guo-rong
openalex   +1 more source

A Systematic Review and Model-Based Meta-Analysis of Pegylated-Interferon-α-Induced HBsAg Loss in Chronic Hepatitis B Virus Infection. [PDF]

CPT Pharmacometrics Syst Pharmacol
Hanan NJ, Zierhut ML, Nader A, Mahajan A, Kaur A, Kumar K, Dixon SA, Das J, Magee M, Theodore D, Gielen V.   +10 more
europepmc   +1 more source

Safety, pharmacokinetics, and pharmacodynamics of the antisense oligonucleotide RO7239958 in healthy volunteers and adults with chronic hepatitis B infection. [PDF]

Antimicrob Agents Chemother
Geretti AM, Sostelly A, Buatois S, Lu S, Lemenuel A, Attley G, Bopst M, Alvarez-Sánchez R, Mueller H, Gane E.   +9 more
europepmc   +1 more source

Evaluation of the Efficacy of Tenofovir Alafenamide in Patients with Low-Level Viremia Under Chronic Hepatitis B Treatment. [PDF]

Viruses
Tahmaz A, Yıldız Dikmen M, Yıldırım F, Öztürk Kaygusuz T, Karabay O, Çelen MK, Alkan S, Damar Çakırca T, Akgül F, Akhan S, Gürbüz E, Özer Balin Ş, Çelik M, Çabalak M.   +13 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Chronic hepatitis B

Current Treatment Options in Gastroenterology, 2004
Interferon alpha, lamivudine, and adefovir are the three drugs currently approved for the treatment of chronic hepatitis B virus (HBV). There are pros and cons associated with the use of each drug. Individualization of therapy, based upon factors such as patient comorbidities, response to prior therapies, and stage of disease, is recommended.
Stephanie D, Straley, Norah A, Terrault
openaire   +2 more sources

Chronic Hepatitis B Infection

Clinics in Liver Disease, 2012
The management of chronic hepatitis B virus (HBV) infection requires understanding the natural history of the disease as well as the risks, benefits, and limitations of the therapeutic options. This article covers the principles governing when to start antiviral therapy, discusses recent advances using hepatitis B surface antigen quantification to ...
Alexander, Kuo, Robert, Gish
openaire   +2 more sources

Interferon in chronic hepatitis B

Antiviral Research, 1994
In patients with typical chronic hepatitis B (HBsAg, HBeAg, HBV-DNA-positive), treatment with interferon-alpha must be carried out for 4-6 months on an alternate-day basis and dosage should be not less than 5 million units/square meter of body surface.
SARACCO, Giorgio Maria, RIZZETTO, Mario, Verme, G.   +2 more
openaire   +3 more sources